Efficacy and safety of low dose rhBNP combined with sacubitril valsartan sodium in patients with coro-nary heart disease and acute heart failure
10.3969/j.issn.1008-0074.2025.05.12
- VernacularTitle:小剂量重组人脑利钠肽联合沙库巴曲缬沙坦钠治疗冠心病合并急性心力衰竭的疗效及安全性
- Author:
Ya-jie WANG
1
;
Fan WANG
1
Author Information
1. 应急总医院药学部,北京市 100028
- Publication Type:Journal Article
- Keywords:
Coronary heart disease;
Heart failure;
Recombinant human brain natriuretic peptide;
Sacubactril/val-sartan
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2025;34(5):658-663
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of low dose recombinant human brain natriuretic peptide(rhBNP)combined with sacubitril valsartan sodium in patients with coronary heart disease and acute heart failure.Methods:This randomized controlled study enrolled 110 patients with coronary heart disease and acute heart failure admitted in Emergency General Hospital between January 2021 and December 2023.Patients were randomly divided into intervention group and control group with 55 cases in each group.Patients in the control group received low dose rhBNP,and those in the intervention group received additional sacubitril valsartan sodium.After 3-month treatment,the clinical efficacy,cardiac function indexes,coronary blood flow reserve,myocardial injury markers,and the incidence of adverse reactions were compared between the two groups.Results:Compared to those in the control group,patients in the intervention group had significantly higher total effective rate(90.57％vs.75.47％,P=0.039).Compared to patients in the control group,those in the intervention group had significantly higher left ventricular ejection fraction[(67.12±6.93)％vs.(62.09±6.81)％,P＜0.001],cardiac output[(4.81±0.79)L/min vs.(4.02±0.71)L/min,P＜0.001],coronary blood flow reserve[(3.62±0.59)vs.(3.09±0.53),P＜0.001],blood flow reserve[(0.95±0.24)vs.(0.79±0.21),P＜0.001],peak flow velocity[(65.22±6.28)cm/s vs.(59.65±6.04)cm/s,P＜0.001],and significantly lower left ventricular end-diastolic diameter[(51.81±4.98)mm vs.(56.02±5.74)mm,P＜0.001],left ventricular end-diastolic volume[(90.72±8.83)ml vs.(98.76±9.23)ml,P＜0.001],creatine kinase isoenzyme[(20.34±3.84)U/L vs.(25.35±4.03)U/L,P＜0.001],lactate dehydrogenase[(224.67±23.81)U/L vs.(247.57±28.34)U/L,P＜0.001],alpha hydroxy bu-tyric acid dehydrogenase[(192.38±20.37)U/L vs.(209.16±22.25)U/L,P＜0.001],and N terminal pro brain natriuretic peptide[(314.39±34.72)pg/ml vs.(351.73±38.13)pg/ml,P＜0.001].There was no significant difference in the incidence of adverse reactions between two groups(P=0.506).Conclusion:This study showed that low dose rhBNP combined with sacubitril valsartan sodium was more effective in the treatment of coronary heart dis-ease and acute heart failure compared to low dose rhBNP alone.No significant difference in the adverse reactions was observed between two groups.
